In experimental studies, Gal-3 suppression prevented the synthesis of profibrotic and proinflammatory markers in multiple tissues, which suggests a possible therapeutic usefulness in DCM [114]. This evidence concerns the gene LGALS3 and familial dilated cardiomyopathy.